Literature DB >> 16419083

RNAi-based suppression and replacement of rds-peripherin in retinal organotypic culture.

Arpad Palfi1, Marius Ader, Anna-Sophia Kiang, Sophia Millington-Ward, Gerry Clark, Mary O'Reilly, Helena P McMahon, Paul F Kenna, Peter Humphries, G Jane Farrar.   

Abstract

Extensive mutational heterogeneity presents a significant barrier to the development of therapeutics for RDS-peripherin-linked autosomal-dominant retinitis pigmentosa (RP), for which more than 50 disease-related mutations have been identified to date. Mutation-independent suppression, using RNA interference (RNAi), together with simultaneous expression of a replacement rds gene (r-rds, which has been altered to escape suppression but nevertheless encodes wild-type protein) has been explored in COS-7 cells and mouse retinal explants. The efficacy of small interfering and short hairpin RNAs (si/shRNAs) silencing mouse rds, and the function of r-rds (containing degenerate substitutions in the RNAi target sequence) were analyzed at transcript (RT-PCR) and protein (ELISA) levels in COS-7 cells. "Dual-" and "triple-expression" constructs carrying the shRNA suppressor and the marker EGFP with or without the r-rds cassette were electroporated in vitro into retinal explants from 1-day-old pups. The retinae were dissociated at day 14, and transduced cells were FACS-sorted using the coexpressed EGFP marker and analyzed by RT-PCR. si/shRNAs decreased rds mRNA and protein expression by up to 82%, while r-rds was protected from suppression in COS-7 cells. Similarly, efficient RNAi-mediated suppression of endogenous rds was detected in retinal explants, while concomitant rescue of r-rds was also achieved. These data validate the concept of RNAi-based suppression coupled with replacement technology for the development of therapies targeting RDS-linked autosomal-dominant RP, and suggest that such approaches could potentially be used for other autosomal-dominant diseases with similarly extensive intragenic heterogeneity. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16419083     DOI: 10.1002/humu.20287

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  20 in total

1.  Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy.

Authors:  Naomi Chadderton; Sophia Millington-Ward; Arpad Palfi; Mary O'Reilly; Gearóid Tuohy; Marian M Humphries; Tiansen Li; Peter Humphries; Paul F Kenna; G Jane Farrar
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

Review 2.  Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors:  A Guzman-Aranguez; P Loma; J Pintor
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

3.  Gene delivery to the retina: from mouse to man.

Authors:  Jean Bennett; Daniel C Chung; Albert Maguire
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

4.  Mutation-independent rescue of a novel mouse model of Retinitis Pigmentosa.

Authors:  D L Greenwald; S M Cashman; R Kumar-Singh
Journal:  Gene Ther       Date:  2012-07-19       Impact factor: 5.250

5.  AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa.

Authors:  Haoyu Mao; Thomas James; Alison Schwein; Arseniy E Shabashvili; William W Hauswirth; Marina S Gorbatyuk; Alfred S Lewin
Journal:  Hum Gene Ther       Date:  2011-03-07       Impact factor: 5.695

6.  Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector.

Authors:  Artur V Cideciyan; Raghavi Sudharsan; Valérie L Dufour; Michael T Massengill; Simone Iwabe; Malgorzata Swider; Brianna Lisi; Alexander Sumaroka; Luis Felipe Marinho; Tatyana Appelbaum; Brian Rossmiller; William W Hauswirth; Samuel G Jacobson; Alfred S Lewin; Gustavo D Aguirre; William A Beltran
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-20       Impact factor: 11.205

Review 7.  Gene therapy for PRPH2-associated ocular disease: challenges and prospects.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-28       Impact factor: 6.915

8.  A common microRNA signature in mouse models of retinal degeneration.

Authors:  Carol J Loscher; Karsten Hokamp; John H Wilson; Tiansen Li; Peter Humphries; G Jane Farrar; Arpad Palfi
Journal:  Exp Eye Res       Date:  2008-09-13       Impact factor: 3.467

9.  Variables and strategies in development of therapeutic post-transcriptional gene silencing agents.

Authors:  Jack M Sullivan; Edwin H Yau; Tiffany A Kolniak; Lowell G Sheflin; R Thomas Taggart; Heba E Abdelmaksoud
Journal:  J Ophthalmol       Date:  2011-06-30       Impact factor: 1.909

10.  RNA interference-mediated suppression and replacement of human rhodopsin in vivo.

Authors:  Mary O'Reilly; Arpad Palfi; Naomi Chadderton; Sophia Millington-Ward; Marius Ader; Thérèse Cronin; Thérèse Tuohy; Alberto Auricchio; Markus Hildinger; Amanda Tivnan; Niamh McNally; Marian M Humphries; Anna-Sophia Kiang; Pete Humphries; Paul F Kenna; G Jane Farrar
Journal:  Am J Hum Genet       Date:  2007-05-23       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.